ST. PAUL, Minn., Oct. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
Date: | Thursday, Nov. 6, 2025 |
Time: | 3:30 p.m. CST / 4:30 p.m. EST |
Location: | |
U.S. dial-in | +1 (800) 715-9871 |
International dial-in: | +1 (646) 307-1963 |
Conference ID: | 6342275 |
A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures will be available on the Investor Relations section of Solventum's website.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.
| Last Trade: | US$71.44 |
| Daily Change: | -0.83 -1.15 |
| Daily Volume: | 697,344 |
| Market Cap: | US$12.390B |
October 21, 2025 August 07, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
